COLLABORATIONS AND ALLIANCES (Detail Textuals) - USD ($) $ in Thousands		1 Months Ended			3 Months Ended		6 Months Ended
	Nov. 03, 2015	Jan. 31, 2013	Feb. 28, 2011	Dec. 31, 2008	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Baseline Contractual Rate							20.00%
Notice period for termination of contract prior to start of specified period							90 days
Notice period for termination of contract post start of Phase 3 clinical trials							180 days
Net revenues					$ 1,072	$ 3,004	$ 2,299	$ 5,789
Phase 3 collaboration costs
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Total milestone partially offset	$ 155,000
Cumulative share of phase 3 collaboration costs in excess of milestones amounts received							64,700
Cumulative share of phase 3 collaboration costs							104,700
Milestone payment received		$ 15,000	$ 25,000
Non-Phase 3 tivantinib collaboration costs
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Contra revenue from non-phase 3 cost less than collaboration partner's share					78
Revenue from non-phase 3 in excess of collaboration partner's share						229
Net revenues								240
Daiichi Sankyo Tivantinib Agreement
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Upfront payment received				$ 60,000
Additional potential development and sales milestone payments				$ 560,000
Milestone payments for official acceptance of drug approval applications	55,000
Milestone payments to be received upon regulatory approvals and first commercial sales	$ 100,000
Net revenues					600	$ 1,600	1,400	$ 2,900
Deferred revenue					$ 1,400		$ 1,400